Known side effects (class effects similar to other GLP-1 medications) Gastrointestinal issues (very common): Nausea: 38-43% of participants vs 11% placebo Diarrhea: 33-35% vs 13% placebo Vomiting: 20-21% vs 0% placebo Constipation: 22-25% vs 9% placebo Decreased appetite: 18-19% vs 9% placebo These are expected with incretin-based therapies and typically improve over time as your body adjusts
TSA allows injectable medications through security with proper documentation
That clinical pattern is now backed by data
[2] For patients new to injectable semaglutide, healthcare providers typically initiate therapy at a lower dose (0.25 mg weekly for Ozempic and Wegovy) and gradually titrate upward every four weeks to minimize gastrointestinal adverse effects
In AWARD-10 [31], a 24-week, randomized, double-blind, placebo-controlled trial evaluating once-weekly dulaglutide (administered at either 1.5 or 0.75 mg) as add-on therapy to SGLT2is in a total of 424 patients with inadequately controlled T2DM, only one episode of severe hypoglycemia was reported throughout the study, in a patient treated with dulaglutide 0.75 mg, confirming the very low incidence of serious hypoglycemia with GLP-1RAs in combination with SGLT2is [31]
A study of 42,000 adults found increased rates of hypotension events after starting GLP-1s
&srotate=0)
